Hoth Therapeutics reports positive Phase 2a interim data for HT-001: 50% reduction in pruritus by Day 21

Hoth Therapeutics, Inc.

Mean pruritus score dropped 50% from 1.6 to 0.8 by Day 21 in open-label portion of CLEER-001 Phase 2a trial.
Rapid symptom relief: mean score improved to 1.0 by Day 7; some patients achieved complete resolution within 21 days.
HT-001 was well tolerated with no treatment-related serious adverse events reported.
Director Graig Springer resigned effective April 15, 2025; Wayne Linsley appointed as chair of nominating and governance committee.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Graig Springer

Director

HOTH · Hoth Therapeutics, Inc.

Effective: 2025-04-15
Filed: April 15, 2025, 7:59 PM ET

On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Graig Springer resigned as Director at Hoth Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.

View on SEC.gov

Hoth Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-031763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.